Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-87 vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing c AMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Management of severe acute pain in opioid-tolerant patients requiring opioid analgesia,Anesthesia induction and maintenance,Supplemental analgesia during regional anesthesia,Procedural sedation and analgesia (off-label),Chronic pain management in opioid-tolerant patients (off-label)
Mild to moderate pain,Pain accompanied by fever
IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 3–12 hours (mean 7 hours) in adults; prolonged to up to 20–30 hours in elderly, critically ill, or patients with hepatic impairment. Context-sensitive half-life increases with infusion duration.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Fentanyl undergoes extensive hepatic metabolism via CYP3A4-mediated N-dealkylation to norfentanyl, along with other minor pathways; elimination is primarily renal.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily hepatic metabolism (>90%) to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for approximately 75% of total elimination, with about 9% excreted unchanged in urine. Fecal excretion is minimal (<9%).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 80–85% bound to plasma proteins (primarily alpha-1-acid glycoprotein and albumin). Increased free fraction in hypoalbuminemia.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
4–6 L/kg (large, extensive tissue distribution). High Vd reflects rapid redistribution from blood to tissues (muscle, fat).
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Intravenous: 100%; intramuscular: ~90%; oral transmucosal: ~50% (range 25–70%, first-pass hepatic metabolism); intranasal: ~50–90%; transdermal: ~30–50% (variable, rate-limited by skin barrier).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No specific dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider dose reduction by 50% or increase dosing interval. Caution in renal impairment due to potential accumulation of metabolites.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution; consider 75% dose reduction. Monitor for prolonged effect.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
IV bolus: 1-2 mcg/kg for analgesia; for sedation/analgesia: 1-2 mcg/kg followed by infusion 0.5-2 mcg/kg/hr. Transdermal: Not recommended for opioid-naive pediatric patients. Transmucosal: Not recommended for children under 2 years.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Reduce initial dose by 50% compared to younger adults. Titrate slowly; monitor for respiratory depression and constipation. Consider using lower strength transdermal patches (12 mcg/h or 25 mcg/h).
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Fentanyl carries a risk of respiratory depression, abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur with prolonged use during pregnancy.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Life-threatening respiratory depression; risk of serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; severe hypotension; bradycardia; use in patients with head injuries or increased intracranial pressure; opioid-induced hyperalgesia; withdrawal if abruptly discontinued.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; hypersensitivity to fentanyl.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No significant food interactions have been reported. However, fentanyl should be taken on an empty stomach only when specified by the prescriber for transmucosal formulations. Grapefruit juice may theoretically increase fentanyl levels due to CYP3A4 inhibition, but clinical significance is minimal; avoid large amounts.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second/third trimester: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome; avoid prolonged high-dose use.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Fentanyl is excreted in breast milk; M/P ratio approximately 0.4. Low concentrations in milk; use with caution in neonates due to potential respiratory depression or withdrawal.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Pregnancy increases clearance and volume of distribution; may require higher doses for analgesia in third trimester; monitor for reduced effect and adjust accordingly.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Fentanyl is 50-100 times more potent than morphine. For opioid-naive patients, start with the lowest effective dose. Monitor for respiratory depression, especially during initiation and dose titration. Consider co-administration of naloxone for home use in patients at high risk for overdose (e.g., high doses, concurrent benzodiazepine use). Transdermal patches are contraindicated in acute pain due to slow onset. Do not heat or cut fentanyl patches. In patients with renal impairment, fentanyl is preferred over morphine due to lack of active metabolites that accumulate.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Do not stop taking this medication abruptly; it may cause withdrawal symptoms.,Do not drive or operate heavy machinery until you know how fentanyl affects you.,Keep this medication in a safe place away from children and pets.,Do not consume alcohol or sedatives while taking fentanyl.,Seek emergency medical help if you have trouble breathing, excessive drowsiness, or fainting.,Do not apply heat (heating pad, hot tub) to the patch site as it may increase absorption.,Dispose of used patches by folding adhesive sides together and flushing down toilet.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-87 vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
FENTANYL-87 is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing c AMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-87 and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-87 is: IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-87 and ACETAMINOPHEN AND CODEINE PHOSPHATE. The risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-87 is classified as Category D/X. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second/third trimester: Chronic use may cause fetal opioid dependence . ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.